Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection

DSpace/Manakin Repository

Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection

Citable link to this page

 

 
Title: Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection
Author: Youngster, Ilan; Mahabamunuge, Jasmin; Systrom, Hannah K.; Sauk, Jenny; Khalili, Hamed; Levin, Joanne; Kaplan, Jess L.; Hohmann, Elizabeth L.

Note: Order does not necessarily reflect citation order of authors.

Citation: Youngster, Ilan, Jasmin Mahabamunuge, Hannah K. Systrom, Jenny Sauk, Hamed Khalili, Joanne Levin, Jess L. Kaplan, and Elizabeth L. Hohmann. 2016. “Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection.” BMC Medicine 14 (1): 134. doi:10.1186/s12916-016-0680-9. http://dx.doi.org/10.1186/s12916-016-0680-9.
Full Text & Related Files:
Abstract: Background: Fecal microbiota transplantation (FMT) has been shown to be safe and effective in treating refractory or relapsing C. difficile infection (CDI), but its use has been limited by practical barriers. We recently reported a small preliminary feasibility study using orally administered frozen fecal capsules. Following these early results, we now report our clinical experience in a large cohort with structured follow-up. Methods: We prospectively followed a cohort of patients with recurrent or refractory CDI who were treated with frozen, encapsulated FMT at our institution. The primary endpoint was defined as clinical resolution whilst off antibiotics for CDI at 8 weeks after last capsule ingestion. Safety was defined as any FMT-related adverse event grade 2 or above. Results: Overall, 180 patients aged 7–95 years with a minimal follow-up of 8 weeks were included in the analysis. CDI resolved in 82 % of patients after a single treatment, rising to a 91 % cure rate with two treatments. Three adverse events Grade 2 or above, deemed related or possibly related to FMT, were observed. Conclusions: We confirm the effectiveness and safety of oral administration of frozen encapsulated fecal material, prepared from unrelated donors, in treating recurrent CDI. Randomized studies and FMT registries are still needed to ascertain long-term safety.
Published Version: doi:10.1186/s12916-016-0680-9
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016994/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:29407899
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters